Latest Stories
3 Reasons to Avoid RGA and 1 Stock to Buy Instead
Reinsurance Group of America currently trades at $201.70 per share and has shown little upside over the past six months, posting a middling return of 3.2%. The stock also fell short of the S&P 500’s 13.6% gain during that period.
Monarch (MCRI): Buy, Sell, or Hold Post Q3 Earnings?
Monarch has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 18.1% to $99.46 per share while the index has gained 13.6%.
3 Reasons JAZZ is Risky and 1 Stock to Buy Instead
The past six months have been a windfall for Jazz Pharmaceuticals’s shareholders. The company’s stock price has jumped 50.6%, hitting $163 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
3 Reasons AMSC Has Explosive Upside Potential
Over the past six months, American Superconductor’s shares (currently trading at $29.00) have posted a disappointing 6% loss, well below the S&P 500’s 13.6% gain. This might have investors contemplating their next move.
3 Reasons to Sell AOS and 1 Stock to Buy Instead
While the S&P 500 is up 13.6% since June 2025, A. O. Smith (currently trading at $68.05 per share) has lagged behind, posting a return of 7.9%. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
3 Big Reasons to Love NMI Holdings (NMIH)
NMI Holdings currently trades at $40.70 per share and has shown little upside over the past six months, posting a middling return of 0.8%. The stock also fell short of the S&P 500’s 13.6% gain during that period.
P10 (PX): Buy, Sell, or Hold Post Q3 Earnings?
P10 trades at $9.83 and has moved in lockstep with the market. Its shares have returned 9.1% over the last six months while the S&P 500 has gained 13.6%.
2 Reasons to Watch VRTX and 1 to Stay Cautious
Since June 2025, Vertex Pharmaceuticals has been in a holding pattern, posting a small return of 0.5% while floating around $450.68. The stock also fell short of the S&P 500’s 13.6% gain during that period.
3 Reasons AIN is Risky and 1 Stock to Buy Instead
Albany’s stock price has taken a beating over the past six months, shedding 25.3% of its value and falling to $50.29 per share. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
3 Reasons to Sell OZK and 1 Stock to Buy Instead
Although Bank OZK (currently trading at $48.25 per share) has gained 7.4% over the last six months, it has trailed the S&P 500’s 13.6% return during that period. This was partly due to its softer quarterly results and might have investors contemplating their next move.